Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cell surface expression of CD25 antigen (surface IL-2 receptor α-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients.
Shvidel L, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, Tadmor T, Klepfish A, Ruchlemer R, Shtalrid M, Berrebi A, Polliack A; Israeli CLL Study Group. Shvidel L, et al. Among authors: braester a. Ann Hematol. 2012 Oct;91(10):1597-602. doi: 10.1007/s00277-012-1492-4. Epub 2012 May 24. Ann Hematol. 2012. PMID: 22623161
Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases.
Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, Klepfish A, Shtalrid M, Berrebi A, Polliack A; Israeli CLL Study Group (ICLLSG). Shvidel L, et al. Among authors: braester a. Ann Hematol. 2013 May;92(5):661-7. doi: 10.1007/s00277-012-1663-3. Epub 2012 Dec 29. Ann Hematol. 2013. PMID: 23274356
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Ofran Y. Merkel D, et al. Among authors: braester a. Am J Hematol. 2013 Feb;88(2):130-4. doi: 10.1002/ajh.23368. Am J Hematol. 2013. PMID: 23345248 Free article.
Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group.
Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, Klepfish A, Ruchlemer R, Berrebi A, Polliack A; Israeli CLL Study Group. Shvidel L, et al. Among authors: braester a. Eur J Haematol. 2014 Jul;93(1):29-33. doi: 10.1111/ejh.12290. Epub 2014 Mar 12. Eur J Haematol. 2014. PMID: 24547751
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
Ofran Y, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Merkel D. Ofran Y, et al. Among authors: braester a. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e95-9. doi: 10.1016/j.clml.2015.02.030. Epub 2015 Mar 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25819366
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Mittelman M, Filanovsky K, Ofran Y, Rosenbaum H, Raanani P, Braester A, Goldschmidt N, Kirgner I, Herishanu Y, Perri C, Ellis M, Oster HS; Israel Myelodysplastic Syndrome Working Group (MDS-WG). Mittelman M, et al. Among authors: braester a. Ann Hematol. 2016 Oct;95(11):1811-8. doi: 10.1007/s00277-016-2776-x. Epub 2016 Aug 22. Ann Hematol. 2016. PMID: 27546027 Clinical Trial.
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.
Haran M, Mirkin V, Braester A, Harpaz N, Shevetz O, Shtreiter M, Greenberg S, Mordich O, Amram O, Binsky-Ehrenreich I, Marom A, Shachar I, Herishanu Y, Ruchlemer R, Berrebi A, Valinsky L, Shtalrid M, Shvidel L. Haran M, et al. Among authors: braester a. Br J Haematol. 2018 Jul;182(1):125-128. doi: 10.1111/bjh.14726. Epub 2017 May 3. Br J Haematol. 2018. PMID: 28466956 Free article. Clinical Trial. No abstract available.
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.
Joffe E, Ariela Arad N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, Shvidel L, Greenbaum U, Aviv A, Tadmor T, Braester A, Goldschmidt N, Polliack A, Herishanu Y. Joffe E, et al. Among authors: braester a. Hematol Oncol. 2018 Feb;36(1):128-135. doi: 10.1002/hon.2444. Epub 2017 Jun 22. Hematol Oncol. 2018. PMID: 28639416
151 results